Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

OnCore Login
Login to Oncore Network

Login to Oncore Network

Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

HCRN investigators to present four studies during ASCO 2022 Annual Meeting

Four Hoosier Cancer Research Network (HCRN) investigator-initiated clinical trials will be highlighted during the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
HCRN investigators will present one poster and three trials in progress posters during the 2022 ASCO annual meeting.

Poster Session:

HCRN MEL16-252: Salvo: Single-arm trial of ipilimumab and nivolumab as adjuvant therapy for resected mucosal melanoma will be presented by Lisa A. Kottschade, APRN, CNP, MSN, of Mayo Clinic.

Authors include: Lisa A. Kottschade, Gregory Russell Pond, Anthony J. Olszanski, Yousef Zakharia, Evidio Domingo-Musibay, Ralph J. Hauke, Brendan D. Curti, Sarah Schober, Mohammed M. Milhem, Matthew Stephen Block, Robert R. McWilliams

Participating institutions: Fox Chase Cancer Center, Mayo Clinic – Florida, Mayo Clinic – Minnesota, Nebraska Cancer Specialists, Providence Portland Medical Center, University of Iowa Hospital and Clinics, University of Minnesota

Trials In Progress:

HCRN GU18-343: A phase II study of cabozantinib in combination with atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer (ABATE), will be presented by Deepak Kilari, MD, from the Froedtert Cancer Center.

Authors include: Deepak Kilari, Aniko Szabo, Abhishek Tripathi, Asit K. Paul, Robert S. Alter, Kathryn A. Bylow, Ariel Ann Nelson, William A. Hall, Peter Langenstroer, Kenneth Jacobsohn, Brian I. Rini, Peter J. Van Veldhuizen, Scott Johnson, Nancy B. Davis, Chunkit Fung, Matthew I. Milowsky

Participating institutions: Froedtert & the Medical College of Wisconsin, John Theurer Cancer Center at Hackensack Meridian Health, University of Rochester Medical Center – Wilmot Cancer Institute, Vanderbilt-Ingram Cancer Center. 

HCRN GI19-405: An open-label, multicenter, randomized phase II study of atezolizumab and bevacizumab with Y90 TARE in patients with unresectable hepatocellular carcinoma (HCC) will be presented by Aiwu Ruth He, PhD, MD, of Georgetown University Lombardi Comprehensive Cancer Center.

Authors include: Aiwu Ruth He, Filip Banovac, Renuka V. Iyer, Michael Petroziello, Daniel Brown, Laura Williams Goff, Richard D. Kim, Nainesh Parikh, Beau Toskich, Kevin Kim, Yixing Jiang, Suvranu Ganguli, Matthew H. Kulke, Samantha Ann Armstrong, Matthew Johnson, Rachna T. Shroff, Gregory Woodhead.

Participating institutions: Georgetown Lombardi Comprehensive Cancer Center, Moffitt Cancer Center, Roswell Park Cancer Institute, Vanderbilt-Ingram Cancer Center 

HCRN-GI21-499: A phase Ib/II study of sotorasib combined with chemotherapy for second line treatment of KRAS p. G12C mutated advanced pancreatic cancer will be presented by Devalingam Mahalingam, MD, PhD, of Northwestern University Feinberg School of Medicine

Authors include: Devalingam Mahalingam, Michael Charles Burns, Aparna Kalyan, Sheetal Mehta Kircher, Masha Kocherginsky, Mary Frances Mulcahy, Al Bowen Benson

Participating institutions include: Atlantic Health System, Fred Hutchinson Cancer Research Center, Froedtert and the Medical College of Wisconsin, Mays Cancer Center at UT Health San Antonio, Northwestern University Feinberg School of Medicine and Summit Health.

Meet us at ASCO

HCRN will host in-person meetings for the Breast Cancer, Gastrointestinal, Thoracic, Melanoma and the Genitourinary Clinical Trial Working group during ASCO 2022. To request a calendar invitation, please contact Debbie Schlegel at dschlegel@hoosiercancer.org. Some meetings will have a virtual option for those who cannot attend in person.

Through HCRN’s Clinical Trial Working Groups, investigators receive scientific input from their peers to ensure protocols are well designed and to gauge interest among potential study sites. HCRN facilitates regular virtual meetings to keep all members of the study team apprised of a study’s progress and to address any concerns or challenges that arise.

About Hoosier Cancer Research Network

Hoosier Cancer Research Network (formerly known as Hoosier Oncology Group) conducts innovative cancer research in collaboration with academic and community physicians and scientists across the United States. The organization provides comprehensive clinical trial management and support, from conception through publication. Created in 1984 as a program of the Walther Cancer Institute, Hoosier Cancer Research Network became an independent nonprofit clinical research organization in 2007. Since its founding, Hoosier Cancer Research Network has conducted more than 230 trials in a variety of cancer types and supportive care, resulting in more than 350 publications. More than 9,000 subjects have participated in Hoosier Cancer Research Network clinical trials.